



PROVIDING ANSWERS FOR CANCER PATIENTS

Press release
13 October 2021

Curasight A/S warrant exercise registered at Erhvervsstyrelsen

On Thursday, 7 October 2021, the exercise period for Curasight A/S (“Curasight” or “the Company”) warrants of series TO 1 (“TO 1”) ended. The warrant exercise has now been registered at Erhvervsstyrelsen. The total number of registered shares now amounts to 19,893,891 shares and the share capital amounts to DKK 994,694.55. The conversion from interim shares to ordinary shares will be made on Friday, 15 October 2021, and new shares are expected to be in each of the shareholders’ accounts around Monday, 18 October 2021.

For further information regarding the warrants of series TO 1, please contact:

Sedermera Fondkommission
+46 40 615 14 10
info@sedermera.se
www.sedermera.se

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO
+45 22 83 01 60
uk@curasight.com
www.curasight.com

Curasight A/S is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology provides improved diagnosis and risk stratification in multiple cancer types.